This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Tilt Biotherapeutics Oy. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Ilkka Liikanen: Innovator in Cancer Therapies
Introduction
Ilkka Liikanen is a prominent inventor based in Helsinki, Finland. He has made significant contributions to the fields of life sciences and medicine, particularly in cancer therapies. His innovative work focuses on developing advanced therapeutic methods to combat cancer in humans.
Latest Patents
Liikanen holds a patent for "Oncolytic adenoviruses coding for bi-specific antibodies." This invention relates to the use of oncolytic adenoviral vectors that encode bispecific monoclonal antibodies. The patent outlines methods and applications that utilize these vectors, including their potential use in conjunction with adoptive cell therapies. He has 1 patent to his name.
Career Highlights
Liikanen is associated with Tilt Biotherapeutics Oy, a company dedicated to advancing biotherapeutic solutions. His work at the company emphasizes the development of innovative cancer treatments that leverage cutting-edge technology and scientific research.
Collaborations
Throughout his career, Liikanen has collaborated with notable colleagues, including Akseli Hemminki and Suvi Parviainen. These partnerships have contributed to the advancement of research and development in the field of cancer therapies.
Conclusion
Ilkka Liikanen's contributions to cancer therapies through his innovative patent and work at Tilt Biotherapeutics Oy highlight his commitment to improving human health. His research continues to pave the way for new therapeutic approaches in the fight against cancer.